Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

580 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Anti-aging proof of concept study: results and summary.
Bruce S, Karnik J, Dryer L, Burkholder D. Bruce S, et al. J Drugs Dermatol. 2014 Sep;13(9):1074-81. J Drugs Dermatol. 2014. PMID: 25226008 Clinical Trial.
Changes from baseline were evaluated for each parameter and P values for changes from baseline to each study visit for investigator's assessments and to end-of-study for self-assessments were calculated. ...
Changes from baseline were evaluated for each parameter and P values for changes from baseline to each study visit for investigator's
Efficacy and safety of calcipotriene 0.005% foam for the treatment of plaque-type psoriasis: results of two multicenter, randomized, double-blind, vehicle-controlled, phase III clinical trials.
Feldman SR, Matheson R, Bruce S, Grande K, Markowitz O, Kempers S, Brundage T, Wyres M; U0267-301 & 302 Study Investigators. Feldman SR, et al. Among authors: bruce s. Am J Clin Dermatol. 2012 Aug 1;13(4):261-71. doi: 10.2165/11630710-000000000-00000. Am J Clin Dermatol. 2012. PMID: 22587791 Clinical Trial.
OUTCOME MEASURES: Treatment success was defined as a score of 0 or 1 (clear or almost clear) on the Investigator's Static Global Assessment (ISGA) psoriasis rating scale and a minimum improvement of ISGA score of at least 2 grades from baseline. ...
OUTCOME MEASURES: Treatment success was defined as a score of 0 or 1 (clear or almost clear) on the Investigator's Static Global Asse …
Once-Daily Oral Sarecycline 1.5 mg/kg/day Is Effective for Moderate to Severe Acne Vulgaris: Results from Two Identically Designed, Phase 3, Randomized, Double-Blind Clinical Trials.
Moore A, Green LJ, Bruce S, Sadick N, Tschen E, Werschler P, Cook-Bolden FE, Dhawan SS, Forsha D, Gold MH, Guenthner S, Kempers SE, Kircik LH, Parish JL, Rendon MI, Rich P, Stein-Gold L, Tyring SK, Weiss RA, Nasir A, Schmitz C, Boodhoo TI, Kaoukhov A, Berk DR. Moore A, et al. Among authors: bruce s. J Drugs Dermatol. 2018 Sep 1;17(9):987-996. J Drugs Dermatol. 2018. PMID: 30235387 Clinical Trial.
METHODS: Patients 9-45 years with moderate to severe facial acne (Investigator's Global Assessment [IGA] score ≥ 3, 20-50 inflammatory and ≤ 100 noninflammatory lesions, and ≤ 2 nodules) were randomized 1:1 to sarecycline 1.5 mg/kg/day or placebo for 12 weeks in identicall …
METHODS: Patients 9-45 years with moderate to severe facial acne (Investigator's Global Assessment [IGA] score ≥ 3, 20-50 inflammator …
Treatment Response With Once-Daily Topical Dapsone Gel, 7.5% for Acne Vulgaris: Subgroup Analysis of Pooled Data from Two Randomized, Double-Blind Stu.
Draelos ZD, Rodriguez DA, Kempers SE, Bruce S, Peredo MI, Downie J, Chang-Lin JE, Berk DR, Ruan S, Kaoukhov A. Draelos ZD, et al. Among authors: bruce s. J Drugs Dermatol. 2017 Jun 1;16(6):591-598. J Drugs Dermatol. 2017. PMID: 28686777 Clinical Trial.
Open-Label Study Evaluating the Anti-Aging Effects of a 3-Product, 2-Step Retinol-Rejuvenation System Following 3 Months of Treatment in Subjects With Photodamage.
Bruce S, Barkovic S. Bruce S, et al. J Drugs Dermatol. 2017 Jan 1;16(1):23-28. J Drugs Dermatol. 2017. PMID: 28095529
The Effects of a Daily Skincare Regimen on Maintaining the Benefits Obtained from Previous Chemical Resurfacing Treatments.
Bruce S, Roberts W, Teller C, Colvan L. Bruce S, et al. J Drugs Dermatol. 2016 Sep 1;15(9):1145-50. J Drugs Dermatol. 2016. PMID: 27602981
According to the physician's global assessment, all subjects demonstrated some level of improvement at week 12 compared to baseline. ...
According to the physician's global assessment, all subjects demonstrated some level of improvement at week 12 compared to baseline. …
A randomized, phase 2, dose-ranging study in the treatment of moderate to severe inflammatory facial acne vulgaris with doxycycline calcium.
Leyden JJ, Bruce S, Lee CS, Ling M, Sheth PB, Stewart DM, Werschler WP, Gilbert RD, Kircik L. Leyden JJ, et al. Among authors: bruce s. J Drugs Dermatol. 2013 Jun 1;12(6):658-63. J Drugs Dermatol. 2013. PMID: 23839182 Clinical Trial.
The primary efficacy variables were the dichotomized Investigator's Global Assessment score (success or failure) at week 12 (success defined as ≥ 2 score decrease from baseline) and the absolute change from baseline to week 12 in inflammatory lesion count. ...
The primary efficacy variables were the dichotomized Investigator's Global Assessment score (success or failure) at week 12 (success …
Safety and efficacy of a novel multimodality hydroquinone-free skin brightener over six months.
Bruce S. Bruce S. J Drugs Dermatol. 2013 Mar;12(3):S27-31. J Drugs Dermatol. 2013. PMID: 23545930 Clinical Trial.
A multi-center, open-label study to evaluate the safety and efficacy of a sequential treatment regimen of clobetasol propionate 0.05% spray followed by Calcitriol 3 mg/g ointment in the management of plaque psoriasis.
Brodell RT, Bruce S, Hudson CP, Weiss JS, Colón LE, Johnson LA, Gottschalk RW. Brodell RT, et al. Among authors: bruce s. J Drugs Dermatol. 2011 Feb;10(2):158-64. J Drugs Dermatol. 2011. PMID: 21283920 Clinical Trial.
At the end of four weeks, if the subject's overall disease severity (ODS) was assessed as clear, almost clear, mild or moderate, subjects started treatment with calcitriol 3 μg/g ointment twice daily. Twice-daily treatment with calcitriol 3 μg/g ointment continued for eigh …
At the end of four weeks, if the subject's overall disease severity (ODS) was assessed as clear, almost clear, mild or moderate, subj …
Efficacy of topical azelaic acid (AzA) gel 15% plus oral doxycycline 40 mg versus metronidazole gel 1% plus oral doxycycline 40 mg in mild-to-moderate papulopustular rosacea.
Del Rosso JQ, Bruce S, Jarratt M, Menter A, Staedtler G. Del Rosso JQ, et al. Among authors: bruce s. J Drugs Dermatol. 2010 Jun;9(6):607-13. J Drugs Dermatol. 2010. PMID: 20645521 Clinical Trial.
580 results
Jump to page
Feedback